Physician profile
Matthew Macaluso
NPI 1417144023
$48,641.50
in general payments reported to CMS, 2019-2025
19 companies · $9,166 in 2025
The $9,166 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $2,375 · 2021: $150 · 2022: $1,623 · 2024: $8,215 · 2025: $9,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,125 · Honoraria: $5,200 · Travel and Lodging: $3,648 · Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,125.00 |
| Honoraria | $5,200.00 |
| Travel and Lodging | $3,648.38 |
| Food and Beverage | $1,407.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29,112.96 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $9,145.37 | 2025 | Caplyta |
| Livanova USA, INC. | $6,918.24 | 2022-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Abbott Laboratories | $1,434.63 | 2024-2025 | Infinity |
| Alfasigma USA, INC. | $1,400.00 | 2022 | |
| Corcept Therapeutics | $375.00 | 2020 | |
| Ucb, INC. | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $81.30 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.00 | 2021-2022 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Macaluso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.